Second, data from the TNBC cohort of MARIO-3, our Phase 2 study in collaboration with Roche/Genentech and which we’re evaluating combination of eganelisib with Tecentriq and Abraxene as a front-line treatment in patients with TNBC were presented at San Antonio Breast in December 2020. These data reinforced the potential of eganelisib to overcome resistance to checkpoint inhibition including in patients who progressed on a checkpoint inhibitor as their immediate prior therapy. First, data from MARIO-1 are Phase 1/1b study in collaboration with Bristol-Myers Squibb evaluating eganelisib in combination with Opdivo in patients with advanced solid tumors namely melanoma and squamous cell cancer of the head neck were presented at 60 in November 2020. But before that, I’d like to briefly remind you of the data we presented over the last six months in chronological order and program guidance. Brian Schwartz will discuss next steps for TNBC and UC programs. On today’s call, our Consulting Chief Physician, Dr. Our pre-clinical translational and clinical data have consistently shown that eganelisib has the potential to create a T cell inflamed tumor and microenvironment from a non-T cell environment, sometimes simplified is turning cold tumors hot activating an immune response and increasing PD-L1 expression thus planning for and increasing the effectiveness of checkpoint inhibitors regardless of baseline PD-L1 levels. Over the last six months, we’ve generated important clinical readout from MARIO-1, MARIO-3 and MARIO-275 studies across six different indications, which has led the broad potential of eganelisib’s unique macrophage targeting a new modulating mechanism.
THESSA INFINITE PROGRESS UPDATE
We’re poised to build on this momentum with a substantial update this summer on the triple negative breast cancer data presented at the San Antonio Breast Cancer Symposium with data on at least twice as many patients in addition to providing an update on our future plans in urothelial cancer at a planned corporate event on Tuesday, July 27. We’ve reached an exciting inflection point at Infinity having generated compelling data, which demonstrate the broad potential of eganelisib to improve – treatment regimens in multiple solid tumors. Thanks, Jayne, and thank you to everyone for joining us today. Now, I’d like to turn the call over to Adelene. These forward-looking statements may represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events or otherwise. Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the Risk Factors section of our Annual Report on Form 10-K for 2020 and in other filings we make with the SEC. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies and financial projections. The press release issued this afternoon details our results and is available on our website at. We’ll open the call for Q&A following our remarks. On the call with me today are Adelene Perkins, Chief Executive Officer Larry Bloch, President and Brian Schwartz, Consulting Chief Physician. Welcome to today’s call to discuss our recent business progress and review of our first quarter 2021 financial results. Thank you, Mel, and good afternoon, everyone. Now, I would like to introduce your host for today’s call, Jayne Kauffman. Please be advised that this call is being recorded at Infinity’s request. There will be a question-and-answer session to follow. At this time, all participants are in a listen-only mode. My name is Mel, and I’ll be your operator for today’s call. Welcome to the Infinity Pharmaceuticals Conference Call to Discuss the Company’s Operations and First Quarter 2021 Financial Results. Ladies and gentlemen, thank you for standing by. Jayne Kauffman – Senior Executive CoordinatorĪdelene Perkins – Chief Executive Officerīrian Schwartz – Consulting Chief Physician ( NASDAQ: INFI) Q1 2021 Earnings Conference Call 4:30 PM ET Any further distribution, resale or broadcasting are prohibited.Infinity Pharmaceuticals, Inc.
THESSA INFINITE PROGRESS FREE
a free 10-40 seconds partial preview (available for active users only)Īll audio files are for personal use only. All ordered tracks and order history will be kept in your Shopping Cart.
Log in using the link in "Status" window.Post-Rock/Experimental Djent Instrumental/Acoustic Rock Thessa: '2013 - Infinite Progress - Media Club
0 kommentar(er)
